Publications by authors named "B L M Ykema"
Testicular cancer survivors (TCS) treated with platinum-based chemotherapy have increased cancer risk. Platinum retention in healthy tissue may contribute to carcinogenesis. We assessed total platinum concentrations in plasma, urine, and normal colonic mucosa samples in TCS treated with cisplatin.
View Article and Find Full Text PDFArticle Synopsis
- Testicular cancer survivors (TCS) who received platinum-based chemotherapy are at a higher risk for developing colorectal cancer (CRC) compared to average-risk individuals.
- A study involving TCS from four Dutch hospitals found that 8.7% of them had advanced neoplasia, significantly higher than the 1.7% found in matched controls.
- The results indicate that TCS have a greater prevalence of colorectal neoplasia and advanced neoplasia, suggesting that colonoscopy screenings may be beneficial for this group; further cost-effectiveness studies are needed to determine the best screening practices.
Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups.
Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors.
Article Synopsis
- Non-seminoma testicular cancer survivors have a higher risk of developing colorectal cancer (CRC) when treated with platinum-based chemotherapy, prompting a study on the mismatch repair (MMR) status in these survivors.
- Researchers analyzed 30 cases of CRC in testicular cancer survivors, finding that 17% exhibited MMR deficiencies, compared to 9% in a larger group of primary CRC patients.
- The study revealed that MMR deficiencies in testicular cancer survivors were often linked to genetic mutations, suggesting that cancer treatments may contribute to the development of these rare CRC cases.
Background: Hodgkin's lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia.
Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors.
Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right-sided, were detected, as published previously.